Present or Historical Efforts Related to Clinical Endpoint Predictivity
- 1 Olson, et.al, Regul Toxicol Pharmacol. 2000 Aug;32(1):56-67.
- 2 PSTC initiative http://c-path.org/pstc.cfm
- 3 JPMA TF1 Project
- 4 Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium)
- 5 Liver Toxicity Knowledge Base (LTKB)
- 6 HESI Pro-Arrhythmia
- 7 Utilizing the Mouse Model of the Human Population to Predict DILI
- 8 IMI eTox Initiative
- 9 Disclaimer
Annotation: In this study, the authors analyzed a survey of 12 companies regarding 150 compounds, resulting in 221 human toxicities. They looked to determine if, when a human toxicity was observed, did the nonclinical studies predict it. They found that when they combined the results of the rondent and nonrodent species, there was a 71% concordance rate.
|Yes||True Positive||False Positive|
|No||False Negative||True Negative|
PSTC initiative http://c-path.org/pstc.cfm
Annotation: Focused on biomarker development and screening.
JPMA TF1 Project
Annotation: In this project, clinical Adverse Drug Reactions (ADR's) were identified from submission documents and reviews for drugs approved in Japan between 2001 and 2010. They then determined if the nonclinical studies predicted these ADR's. The study found a 36% concordance between human ADR's and animal toxicity
- This group queried the FDA database for correlations between nonclinical QT changes and clinical effects. They found a moderate correlation ("at best"), with better predictivity at higher clinical exposure multiples. Findings were limited by a number of factors, including small sample size. Koerner, et.al. SOT 2012
- It also appears that this group is collecting additional data from pharma. companies to do additional analysis on this problem.
Utilizing the Mouse Model of the Human Population to Predict DILI
IMI eTox Initiative
FDA comments are an informal communication and represent the individual's best judgment. These comments do not bind or obligate FDA. The contents of this wiki are from the individual contributors and do not necessarily reflect the view and/or policies of the Food and Drug Administration, the employers of the individuals involved or any of their staff.
Last revision by Philippe.Marc,04/12/2017